Chris Gibson, Ph.D.

Chris Gibson, Ph.D.

DirectoratRecursion Pharmaceuticals· In proxies 2021–2025

Pay in FY2025+13% from the year before · Recursion Pharmaceuticals stock -39.5% the same year

Chris Gibson, Ph.D. was paid $9.6M in FY2025 (Dec), up 13%. Recursion Pharmaceuticals stock fell 39.5% that year.

Pay$100 in the stock at the end of FY21 → $24
Pay is from the Summary Compensation Table of each Recursion Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Pacific Biosciences Of CaliforniaPublic company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  2. Recursion PharmaceuticalsPublic company · 5 yr
    • former Chief Executive Officer and President and current Chair of the Board2021 – Present · 5 yrStock in role -86%
  3. Pacific Biosciences of California, Inc.Public company · Less than 1 yr
    • Director2026 – Present · Less than 1 yrNo stock prices for these years
  4. CellinoPublic company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  5. Altitude LabPublic company · 6 yr
    • Director2020 – Present · 6 yrNo stock prices for these years
  6. Development Technology Corporate Social Responsibility DIRECTOR SINCEPublic company · 13 yr
    • Director2013 – Present · 13 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Pacific Biosciences Of CaliforniaDirector · -1 yr on the boardIndependentScience and Technology—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?